December 2025 in “Biomedicines” Tyrosine kinase inhibitors for endocrine tumors often cause skin issues, requiring early management and treatment adjustments.
57 citations
,
August 2006 in “Journal of the American Academy of Dermatology” Gefitinib can cause hair loss without scarring.
Tofacitinib may effectively treat hair loss and improve symptoms in autoimmune conditions like alopecia areata and Sjögren's syndrome, but long-term treatment might be necessary.
36 citations
,
July 2017 in “Journal of controlled release” A new method allows for controlled, long-lasting delivery of retinoic acid through the skin with fewer side effects.
10 citations
,
December 2005 in “Aktuelle Dermatologie” Alfatradiol (0.025%) is an effective and safe treatment for hair loss in both women and men.
July 2025 in “Journal of Investigative Dermatology” 5% ET-02 is a more effective and safe treatment for hair loss than current options.
26 citations
,
January 2019 in “Expert Opinion on Investigational Drugs” New treatments for hair loss show promise, but more research is needed to confirm their safety and effectiveness.
April 2023 in “Journal of Investigative Dermatology” Baricitinib at 2mg and 4mg doses improved work productivity and reduced costs for adults with atopic dermatitis.
October 2023 in “Journal of the American Academy of Dermatology” Clascoterone cream could be used for other skin conditions affected by hormones.
November 2025 in “International Journal of Research in Medical Sciences” Titagen® improves skin, hair, nail health, and reduces osteoarthritis symptoms safely.
June 2014 in “Dermatology Times E-News” An arthritis drug helped a person with severe hair loss regrow their hair.
June 2022 in “Frontiers in Immunology” Tofacitinib regrew hair in a man with total hair loss but raised cytokine levels, needing more research on possible side effects.
June 2026 in “Advanced Healthcare Materials” A new taurine-based liquid can help treat hair loss by improving hair follicle health and promoting regrowth.
1 citations
,
February 2014 in “Archiv Der Pharmazie” Carbamates may help treat androgen-dependent conditions by changing how certain lipid enzymes are produced.
11 citations
,
November 2018 in “Journal of the American Academy of Dermatology” Tofacitinib therapy can effectively regrow eyebrows and eyelashes in some alopecia areata patients.
16 citations
,
July 2017 in “Rheumatology and Therapy” Tofacitinib, a medication for arthritis, showed potential for treating severe hair loss in a small Brazilian case series, but more research is needed.
January 2021 in “Journal of Cancer Therapy” Tyrosine Kinase Inhibitors are effective against cancer but can cause skin, digestive, and blood side effects, including hair loss.
January 2018 in “Springer eBooks” Terbinafine is the most effective medicine for fungal nail infections, especially for diabetics and those with weak immune systems.
November 2024 in “PubMed” Terbinafine can cause skin reactions when exposed to sunlight, so sun exposure should be avoided during treatment.
July 2025 in “Materials Today Bio” TFC-loaded microneedles effectively promote hair regrowth in androgenetic alopecia.
January 2018 in “Figshare” Ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata.
26 citations
,
June 2022 in “Stem Cell Research & Therapy” Tideglusib helps heal wounds in older skin.
22 citations
,
May 2017 in “Journal of dermatological treatment” BD 1/4 dilution is the best for treating localized alopecia areata in adults.
October 2024 in “Journal of the European Academy of Dermatology and Venereology” Ritlecitinib and baricitinib are similarly effective for hair regrowth in severe alopecia areata.
1 citations
,
February 2022 in “Clinical, Cosmetic and Investigational Dermatology” TDM10842, a thyroid hormone receptor activator, was found to effectively promote hair growth in mice.
51 citations
,
May 2008 in “Mycoses” Terbinafine HCl nail solutions with DDAIP HCl are more effective than current treatments for nail infections.
2 citations
,
August 2025 in “Scientific Reports” Pexidartinib often causes liver issues and fatigue, especially in women.
9 citations
,
April 2024 in “The Oncologist” Sacituzumab govitecan improves quality of life and symptoms in breast cancer patients, except for causing more diarrhea.
January 2022 in “Drugs of Today” April 2007 in “Linchuang pifuke zazhi” TGF-β1 and 2 may play a role in hair loss in AGA.